

July 15, 2021

VIA EMAIL

SEC Office of FOIA Services 100 F Street NE Washington, DC 20549-2465 foiapa@sec.gov

Re: Freedom of Information Act Request

Dear FOIA Officer:

Pursuant to the Freedom of Information Act (FOIA), 5 U.S.C. § 552, and the implementing regulations of your agency, 6 C.F.R. Part 5, American Oversight makes the following request for records.

The *Washington Post* reported that Robert Kramer, CEO of Emergent BioSolutions (Emergent), sold more than \$10 million in his company's stock in January and February 2021, shortly before public disclosures of significant problems at Emergent's Baltimore, Maryland factory.¹ When it was revealed that these problems led to the cross-contamination and subsequent loss of 15 million doses of Johnson & Johnson COVID-19 vaccines, Emergent's stock price tumbled: on February 19, Emergent's stock value fell more than 50 percent, from \$125 to \$62 per share.² Recent reports found that the last time Mr. Kramer made substantive sales of his company's stock was in spring 2016.³

In late-April, Sen. Elizabeth Warren sent a letter to the Securities and Exchange Commission (SEC) asking SEC to investigate the stock sale amid concerns surrounding potential insider trading.⁴ While Mr. Kramer responded to the *Washington Post*'s

¹ See, e.g., Jon Swaine, CEO of Vaccine Maker Emergent Sold \$10 Million in Stock Before Company Ruined Johnson & Johnson Doses, Wash. Post (April 25, 2021, 8:48 PM), <u>https://www.washingtonpost.com/investigations/emergent-robert-kramer-stock-sales/2021/04/25/de151434-a2b6-11eb-a7ee-949c574a09ac_story.html;</u> Christopher Rowland, Johnson & Johnson Documented Contamination Risks at Baltimore Plant Months Before Vaccine was Ruined, Wash. Post (May 19, 2021, 11:34 AM), <u>https://www.washingtonpost.com/business/2021/05/19/emergent-johnson-johnson-vaccine-congress/</u>.

 $^{^{2}}$ Id.

³ See Swaine, supra note 1.

⁴ Letter from Sen. Elizabeth Warren to Gary Gensler, Chair, Sec. and Exhange Comm'n, Apr. 27, 2021,

https://www.warren.senate.gov/imo/media/doc/2021.04.27%20Letter%20to%20SEC %20re%20Emergency%20CEO%20stocks.pdf.

reporting by stating that he had made his trading plans on November 13, 2020, it had been reported as early as October 2020 that a batch of AstraZeneca's COVID-19 vaccine being developed at Emergent's plant was discarded due to possible contamination.⁵

American Oversight seeks records with the potential to shed light on Mr. Kramer's stock sales given the challenges identified at Emergent's Maryland factory.

Requested Records

American Oversight requests that the Securities and Exchange Commission (SEC) produce the following records within twenty business days:

Records reflecting any investigation opened into Robert Kramer's sale of Emergent BioSolutions stock during the months of January 2021 and February 2021.

American Oversight believes SEC is best positioned to determine where responsive records may reside. However, American Oversight requests SEC search, at a minimum, the following offices: **Division of Enforcement** and the **Office of the Secretary**.

Please provide all responsive records from November 1, 2020 through the date of the search.

Fee Waiver Request

In accordance with 5 U.S.C. § 552(a)(4)(A)(iii) and your agency's regulations, American Oversight requests a waiver of fees associated with processing this request for records. The subject of this request concerns the operations of the federal government, and the disclosures will likely contribute to a better understanding of relevant government procedures by the general public in a significant way. Moreover, the request is primarily and fundamentally for non-commercial purposes.

American Oversight requests a waiver of fees because disclosure of the requested information is "in the public interest because it is likely to contribute significantly to public understanding of operations or activities of the government."⁶ The public has a significant interest in COVID-19 vaccine development, contracts awarded for its development, and potential deficiencies or mismanagement associated with vaccine manufacturing.⁷ Records with the potential to shed light on this matter would

https://www.nytimes.com/2021/04/06/us/covid-vaccines-emergentbiosolutions.html.

⁵ Chris Hamby et al., U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted, N.Y. Times, updated May 6, 2021,

⁶ 5 U.S.C. § 552(a)(4)(A)(iii).

⁷ See, e.g., Majority Staff, House Select Subcommittee on the Coronavirus Crisis and House Committee on Oversight and Reform, *Memorandum: Preliminary Findings from Investigation into Emergent BioSolutions, Inc.*, May 19, 2021,

contribute significantly to public understanding of federal government operations, including whether and to what extent Mr. Kramer unfairly profited from the sale of millions of dollars' worth of his company's stock. American Oversight is committed to transparency and makes the responses agencies provide to FOIA requests publicly available, and the public's understanding of the government's activities would be enhanced through American Oversight's analysis and publication of these records.

This request is primarily and fundamentally for non-commercial purposes.⁸ As a 501(c)(3) nonprofit, American Oversight does not have a commercial purpose and the release of the information requested is not in American Oversight's financial interest. American Oversight's mission is to promote transparency in government, to educate the public about government activities, and to ensure the accountability of government officials. American Oversight uses the information gathered, and its analysis of it, to educate the public through reports, press releases, or other media. American Oversight also makes materials it gathers available on its public website and promotes their availability on social media platforms, such as Facebook and Twitter.⁹

American Oversight has also demonstrated its commitment to the public disclosure of documents and creation of editorial content through regular substantive analyses posted to its website.¹⁰ Examples reflecting this commitment to the public disclosure of documents and the creation of editorial content include the posting of records related to the Trump Administration's contacts with Ukraine and analyses of those contacts;¹¹ posting records and editorial content about the federal government's response to the Coronavirus pandemic;¹² posting records received as part of American Oversight's "Audit the Wall" project to gather and analyze information related to the administration's proposed construction of a barrier along the U.S.-Mexico border, and analyses of what those records reveal;¹³ the posting of records related to an ethics

<u>https://www.facebook.com/weareoversight/</u> (last visited June 29, 2021); American Oversight (@weareoversight), Twitter, <u>https://twitter.com/weareoversight</u> (last visited June 29, 2021).

https://coronavirus.house.gov/sites/democrats.coronavirus.house.gov/files/Staff%20 Memo%20re%20Emergent%20-%20FINAL.pdf.

⁸ See 5 U.S.C. § 552(a)(4)(A)(iii).

⁹ American Oversight currently has approximately 15,652 page likes on Facebook and 106,000 followers on Twitter. American Oversight, Facebook,

 ¹⁰ See generally News, American Oversight, <u>https://www.americanoversight.org/blog</u>.
¹¹ Trump Administration's Contacts with Ukraine, American Oversight,

https://www.americanoversight.org/investigation/the-trump-administrationscontacts-with-ukraine.

¹² See generally The Trump Administration's Response to Coronavirus, American Oversight, <u>https://www.americanoversight.org/investigation/the-trump-administrations-</u>

response-to-coronavirus; see, e.g., CDC Calendars from 2018 and 2019: Pandemic-Related Briefings and Meetings, American Oversight, <u>https://www.americanoversight.org/cdc-calendars-from-2018-and-2019-pandemic-related-briefings-and-meetings</u>.

¹³ See generally Audit the Wall, American Oversight,

https://www.americanoversight.org/investigation/audit-the-wall; see, e.g., Border Wall Investigation Report: No Plans, No Funding, No Timeline, No Wall, American Oversight,

waiver received by a senior Department of Justice attorney and an analysis of what those records demonstrated regarding the Department's process for issuing such waivers;¹⁴ and posting records and analysis of federal officials' use of taxpayer dollars to charter private aircraft or use government planes for unofficial business.¹⁵

Accordingly, American Oversight qualifies for a fee waiver.

Guidance Regarding the Search & Processing of Requested Records:

In connection with its request for records, American Oversight provides the following guidance regarding the scope of the records sought and the search and processing of records:

- Please search all locations and systems likely to have responsive records, regardless of format, medium, or physical characteristics.
- In conducting your search, please understand the terms "record," "document," and "information" in their broadest sense, to include any written, typed, recorded, graphic, printed, or audio material of any kind. We seek records of any kind, including electronic records, audiotapes, videotapes, and photographs, as well as letters, emails, facsimiles, telephone messages, voice mail messages, and transcripts, notes, or minutes of any meetings, telephone conversations, or discussions.
- Our request for records includes any attachments to those records or other materials enclosed with those records when they were previously transmitted. To the extent that an email is responsive to our request, our request includes all prior messages sent or received in that email chain, as well as any attachments to the email.
- Please search all relevant records or systems containing records regarding agency business. Do not exclude records regarding agency business contained in files, email accounts, or devices in the personal custody of your officials, such as personal email accounts or text messages. Records of official business conducted using unofficial systems or stored outside of official files are subject to the

https://www.americanoversight.org/border-wall-investigation-report-no-plans-no-funding-no-timeline-no-wall.

¹⁴ DOJ Records Relating to Solicitor General Noel Francisco's Recusal, American Oversight, https://www.americanoversight.org/document/doj-civil-division-response-noelfrancisco-compliance; Francisco & the Travel Ban: What We Learned from the DOJ Documents, American Oversight, https://www.americanoversight.org/francisco-thetravel-ban-what-we-learned-from-the-doj-documents.

¹⁵ See generally Swamp Airlines: Chartered Jets at Taxpayer Expense, American Oversight, <u>https://www.americanoversight.org/investigation/swamp-airlines-private-jets-</u> <u>taxpayer-expense</u>; see, e.g., New Information on Pompeo's 2017 Trips to His Home State, American Oversight, <u>https://www.americanoversight.org/new-information-on-</u> <u>pompeos-2017-trips-to-his-home-state</u>.

Federal Records Act and FOIA.¹⁶ It is not adequate to rely on policies and procedures that require officials to move such information to official systems within a certain period of time; American Oversight has a right to records contained in those files even if material has not yet been moved to official systems or if officials have, by intent or through negligence, failed to meet their obligations.¹⁷

- Please use all tools available to your agency to conduct a complete and efficient search for potentially responsive records. Agencies are subject to government-wide requirements to manage agency information electronically,¹⁸ and many agencies have adopted the National Archives and Records Administration (NARA) Capstone program, or similar policies. These systems provide options for searching emails and other electronic records in a manner that is reasonably likely to be more complete than just searching individual custodian files. For example, a custodian may have deleted a responsive email from his or her email program, but your agency's archiving tools may capture that email under Capstone. At the same time, custodian searches are still necessary; agencies may not have direct access to files stored in .PST files, outside of network drives, in paper format, or in personal email accounts.
- In the event some portions of the requested records are properly exempt from disclosure, please disclose any reasonably segregable non-exempt portions of the requested records. If a request is denied in whole, please state specifically why it is not reasonable to segregate portions of the record for release.
- Please take appropriate steps to ensure that records responsive to this request are not deleted by the agency before the completion of processing for this request. If records potentially responsive to this request are likely to be located on systems where they are subject to potential deletion, including on a scheduled basis, please take steps to prevent that deletion, including, as appropriate, by instituting a litigation hold on those records.

Conclusion

If you have any questions regarding how to construe this request for records or believe that further discussions regarding search and processing would facilitate a more

¹⁶ See Competitive Enter. Inst. v. Office of Sci. & Tech. Policy, 827 F.3d 145, 149-50

⁽D.C. Cir. 2016); cf. Judicial Watch, Inc. v. Kerry, 844 F.3d 952, 955–56 (D.C. Cir. 2016). ¹⁷ See Competitive Enter. Inst. v. Office of Sci. & Tech. Policy, No. 14-cv-765, slip op. at 8 (D.D.C. Dec. 12, 2016).

¹⁸ Presidential Memorandum—Managing Government Records, 76 Fed. Reg. 75,423 (Nov. 28, 2011), <u>https://obamawhitehouse.archives.gov/the-press-</u>

office/2011/11/28/presidential-memorandum-managing-government-records; Office of Mgmt. & Budget, Exec. Office of the President, Memorandum for the Heads of

Executive Departments & Independent Agencies, "Managing Government Records Directive," M-12-18 (Aug. 24, 2012), <u>https://www.archives.gov/files/records-</u>mgmt/m-12-18.pdf.

efficient production of records of interest to American Oversight, please do not hesitate to contact American Oversight to discuss this request. American Oversight welcomes an opportunity to discuss its request with you before you undertake your search or incur search or duplication costs. By working together at the outset, American Oversight and your agency can decrease the likelihood of costly and time-consuming litigation in the future.

Where possible, please provide responsive material in an electronic format by email. Alternatively, please provide responsive material in native format or in PDF format on a USB drive. Please send any responsive material being sent by mail to American Oversight, 1030 15th Street NW, Suite B255, Washington, DC 20005. If it will accelerate release of responsive records to American Oversight, please also provide responsive material on a rolling basis.

We share a common mission to promote transparency in government. American Oversight looks forward to working with your agency on this request. If you do not understand any part of this request, please contact Emma Lewis at <u>foia@americanoversight.org</u> or by phone at (202) 919-6303. Also, if American Oversight's request for a fee waiver is not granted in full, please contact us immediately upon making such a determination.

Sincerely,

<u>/s/ Emma Lewis</u> Emma Lewis on behalf of American Oversight